Bank Hapoalim BM Sells 5,363 Shares of Pfizer Inc. $PFE

Bank Hapoalim BM lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 111,255 shares of the biopharmaceutical company’s stock after selling 5,363 shares during the period. Bank Hapoalim BM’s holdings in Pfizer were worth $2,697,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. GKV Capital Management Co. Inc. bought a new position in Pfizer in the first quarter worth approximately $27,000. North Capital Inc. bought a new position in Pfizer in the first quarter worth approximately $28,000. Bayforest Capital Ltd bought a new position in Pfizer in the first quarter worth approximately $28,000. Horizon Financial Services LLC bought a new position in Pfizer in the first quarter worth approximately $35,000. Finally, WPG Advisers LLC bought a new position in Pfizer in the first quarter worth approximately $35,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of a number of recent research reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Morgan Stanley boosted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Finally, UBS Group reaffirmed a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $28.41.

Pfizer Stock Performance

Shares of PFE stock opened at $27.37 on Friday. The business’s fifty day simple moving average is $24.67 and its 200-day simple moving average is $24.15. The company has a market cap of $155.59 billion, a PE ratio of 14.56, a PEG ratio of 0.88 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.